364 related articles for article (PubMed ID: 18986012)
1. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model.
Duman S; Bozkurt D; Sipahi S; Sezak M; Ozkan S; Ertilav M; Sen S; Ok E
Adv Perit Dial; 2008; 24():104-10. PubMed ID: 18986012
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
Bozkurt D; Taskin H; Sezak M; Biçak S; Sen S; Ok E; Duman S
Adv Perit Dial; 2008; 24():32-8. PubMed ID: 18985998
[TBL] [Abstract][Full Text] [Related]
3. Can N-acetylcysteine preserve peritoneal function and morphology in encapsulating peritoneal sclerosis?
Bozkurt D; Hur E; Ulkuden B; Sezak M; Nar H; Purclutepe O; Sen S; Duman S
Perit Dial Int; 2009 Feb; 29 Suppl 2():S202-5. PubMed ID: 19270218
[TBL] [Abstract][Full Text] [Related]
4. The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis.
Bozkurt D; Cetin P; Sipahi S; Hur E; Nar H; Ertilav M; Sezak M; Duman S
Perit Dial Int; 2008 Nov; 28 Suppl 5():S38-42. PubMed ID: 19008539
[TBL] [Abstract][Full Text] [Related]
5. Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis?
Bozkurt D; Sipahi S; Cetin P; Hur E; Ozdemir O; Ertilav M; Sen S; Duman S
Perit Dial Int; 2009 Feb; 29 Suppl 2():S206-10. PubMed ID: 19270219
[TBL] [Abstract][Full Text] [Related]
6. The effects of colchicine on the progression and regression of encapsulating peritoneal sclerosis.
Bozkurt D; Bicak S; Sipahi S; Taskin H; Hur E; Ertilav M; Sen S; Duman S
Perit Dial Int; 2008 Nov; 28 Suppl 5():S53-7. PubMed ID: 19008543
[TBL] [Abstract][Full Text] [Related]
7. Role of tyrosine kinase inhibition with imatinib in an encapsulating peritoneal sclerosis rat model.
Velioglu A; Tugtepe H; Asicioglu E; Yilmaz N; Filinte D; Arikan H; Koc M; Tuglular S; Kaya H; Ozener C
Ren Fail; 2013; 35(4):531-7. PubMed ID: 23473055
[TBL] [Abstract][Full Text] [Related]
8. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model.
Ertilav M; Hur E; Bozkurt D; Sipahi S; Timur O; Sarsik B; Akcicek F; Duman S
Nephrology (Carlton); 2011 Aug; 16(6):552-7. PubMed ID: 21382127
[TBL] [Abstract][Full Text] [Related]
9. The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution.
Günal AI; Celiker H; Ustundag B; Akpolat N; Dogukan A; Akcicek F
J Nephrol; 2003; 16(2):225-30. PubMed ID: 12768069
[TBL] [Abstract][Full Text] [Related]
10. Fibrin degradation products are a useful marker for the risk of encapsulating peritoneal sclerosis.
Moriishi M; Kawanishi H
Adv Perit Dial; 2008; 24():56-9. PubMed ID: 18986002
[TBL] [Abstract][Full Text] [Related]
11. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan.
Hirahara I; Inoue M; Okuda K; Ando Y; Muto S; Kusano E
Nephrol Dial Transplant; 2007 Feb; 22(2):560-7. PubMed ID: 17035369
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum.
Duman S; Wieczorowska-Tobis K; Styszynski A; Kwiatkowska B; Breborowicz A; Oreopoulos DG
Adv Perit Dial; 2004; 20():31-6. PubMed ID: 15384791
[TBL] [Abstract][Full Text] [Related]
13. A novel angiogenesis inhibitor, sunitinib malate, in encapsulating peritoneal sclerosis.
Bozkurt D; Sarsik B; Hur E; Ertilav M; Karaca B; Timur O; Bicak S; Akcicek F; Duman S
J Nephrol; 2011; 24(3):359-65. PubMed ID: 21240876
[TBL] [Abstract][Full Text] [Related]
14. Role of adhesion molecules in the progression of peritoneal sclerosis.
Imai H; Nakamoto H; Fukushima R; Ishida Y; Yamanouchi Y; Suzuki H
Adv Perit Dial; 2003; 19():180-5. PubMed ID: 14763058
[TBL] [Abstract][Full Text] [Related]
15. Additive effectiveness of everolimus plus tamoxifen therapy in treatment of encapsulating peritoneal sclerosis.
Huddam B; Azak A; Koçak G; Başaran M; Voyvoda N; Duranay M
Ren Fail; 2012; 34(3):387-9. PubMed ID: 22263915
[TBL] [Abstract][Full Text] [Related]
16. Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model.
Ceri M; Unverdi S; Dogan M; Unverdi H; Karaca G; Kocak G; Kurultak I; Akbal E; Can M; Duranay M
Int Urol Nephrol; 2012 Jun; 44(3):977-82. PubMed ID: 22528580
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats.
Zareie M; Keuning ED; ter Wee PM; Beelen RH; van den Born J
Nephrol Dial Transplant; 2005 Jan; 20(1):189-93. PubMed ID: 15572385
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis.
Imai H; Nakamoto H; Fucshima R; Yamanouchi Y; Ishida Y; Suzuki H
Adv Perit Dial; 2002; 18():124-30. PubMed ID: 12402603
[TBL] [Abstract][Full Text] [Related]
19. Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies.
Hung KY; Huang JW; Chiang CK; Tsai TJ
Nephrol Dial Transplant; 2008 Dec; 23(12):3831-40. PubMed ID: 18614818
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients.
Alscher DM; Braun N; Biegger D; Fritz P
Am J Kidney Dis; 2007 Mar; 49(3):452-61. PubMed ID: 17336707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
